Literature DB >> 11257469

A new dysferlin gene mutation in two Japanese families with limb-girdle muscular dystrophy 2B and Miyoshi myopathy.

H Ueyama1, T Kumamoto, S Nagao, T Masuda, H Horinouchi, S Fujimoto, T Tsuda.   

Abstract

We found a new dysferlin gene mutation in two Japanese families, one with limb-girdle muscular dystrophy 2B and the other with Miyoshi myopathy. All patients in the limb-girdle muscular dystrophy 2B family showed apparent proximal dominant muscle atrophy and weakness, whereas a patient with Miyoshi myopathy in the second family showed distal muscle involvement at an early stage. The common clinical feature of all patients in both families was preferential involvement of calf muscles rather than the tibialis anterior muscle, which was confirmed by muscle computed tomography scan. All patients in both families shared the same homozygous alleles for chromosome 2p13 markers, and dysferlin gene analysis revealed a novel missense mutation, a G to A transition at nt 5882, which changed aspartic acid to asparagine at codon 1837. Allele-specific polymerase chain reaction analysis was used for confirmation of the mutation and for genotype analysis of the family members.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257469     DOI: 10.1016/s0960-8966(00)00168-1

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  10 in total

Review 1.  Plasma Membrane Repair: A Central Process for Maintaining Cellular Homeostasis.

Authors:  Alisa D Blazek; Brian J Paleo; Noah Weisleder
Journal:  Physiology (Bethesda)       Date:  2015-11

2.  Treatment with Recombinant Human MG53 Protein Increases Membrane Integrity in a Mouse Model of Limb Girdle Muscular Dystrophy 2B.

Authors:  Liubov V Gushchina; Sayak Bhattacharya; Kevin E McElhanon; Jin Hyuk Choi; Heather Manring; Eric X Beck; Jenna Alloush; Noah Weisleder
Journal:  Mol Ther       Date:  2017-07-03       Impact factor: 11.454

3.  Novel diagnostic features of dysferlinopathies.

Authors:  Xiomara Q Rosales; Julie M Gastier-Foster; Sarah Lewis; Malik Vinod; Devon L Thrush; Caroline Astbury; Robert Pyatt; Shalini Reshmi; Zarife Sahenk; Jerry R Mendell
Journal:  Muscle Nerve       Date:  2010-07       Impact factor: 3.217

Review 4.  Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies.

Authors:  Myrsini Chamakioti; Nikolaos Karantzelis; Stavros Taraviras
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

5.  Dysferlinopathy course and sportive activity: clues for possible treatment.

Authors:  C Angelini; E Peterle; A Gaiani; L Bortolussi; C Borsato
Journal:  Acta Myol       Date:  2011-10

6.  Autosomal recessive limb-girdle muscular dystrophies in the Czech Republic.

Authors:  Kristýna Stehlíková; Daniela Skálová; Jana Zídková; Lenka Mrázová; Petr Vondráček; Radim Mazanec; Stanislav Voháňka; Jana Haberlová; Markéta Hermanová; Josef Zámečník; Ondřej Souček; Hana Ošlejšková; Nina Dvořáčková; Pavla Solařová; Lenka Fajkusová
Journal:  BMC Neurol       Date:  2014-08-19       Impact factor: 2.474

7.  Exome sequencing identifies novel dysferlin mutation in a family with pauci-symptomatic heterozygous carriers.

Authors:  Mahjoubeh Jalali-Sefid-Dashti; Melissa Nel; Jeannine M Heckmann; Junaid Gamieldien
Journal:  BMC Med Genet       Date:  2018-06-07       Impact factor: 2.103

8.  Progression to Loss of Ambulation Among Patients with Autosomal Recessive Limb-girdle Muscular Dystrophy: A Systematic Review.

Authors:  Ivana F Audhya; Antoinette Cheung; Shelagh M Szabo; Emma Flint; Conrad C Weihl; Katherine L Gooch
Journal:  J Neuromuscul Dis       Date:  2022

9.  Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial.

Authors:  Maggie C Walter; Peter Reilich; Simone Thiele; Joachim Schessl; Herbert Schreiber; Karlheinz Reiners; Wolfram Kress; Clemens Müller-Reible; Matthias Vorgerd; Peter Urban; Bertold Schrank; Marcus Deschauer; Beate Schlotter-Weigel; Ralf Kohnen; Hanns Lochmüller
Journal:  Orphanet J Rare Dis       Date:  2013-02-14       Impact factor: 4.123

10.  Dysferlinopathy in Switzerland: clinical phenotypes and potential founder effects.

Authors:  Jens A Petersen; Thierry Kuntzer; Dirk Fischer; Maja von der Hagen; Angela Huebner; Veronika Kana; Johannes A Lobrinus; Wolfram Kress; Elisabeth J Rushing; Michael Sinnreich; Hans H Jung
Journal:  BMC Neurol       Date:  2015-10-06       Impact factor: 2.474

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.